source
- Zura Bio halts hidradenitis suppurativa program after tibulizumab fails phase 2 trialZura Bio announced it is ending development of tibulizumab for hidradenitis suppurativa after the drug did not meet the primary endpoint in a phase 2 study. The trial, called Tibushield, compared t…
- Vir Biotechnology's Phase 3 Trial Shows Primary Endpoint Success in Chronic Hepatitis DeltaVir Biotechnology reported that its phase 3 Eclipse 1 trial in chronic hepatitis delta met the primary endpoint. At week 48, 44% of patients who began treatment immediately showed undetectable HDV…